Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Larsucosterol · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Larsucosterol 30 mg | EXPERIMENTAL | Participants will receive Larsucosterol 30 milligrams (mg) intravenous infusion on Day 1. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive intravenous infusion of placebo matched to Larsucosterol on Day 1. |
| Name | Type | Description |
|---|---|---|
| Larsucosterol | DRUG | Larsucosterol intravenous infusion. |
| Placebo | DRUG | Matching-placebo (sterile water for injection) intravenous infusion. |
Inclusion Criteria- A participant will be eligible for inclusion in this study if he/she meets all the following criteria: 1. Able to provide written informed consent (either from participant or participant's legally acceptable representative). 2. Onset of jaundice within 8 weeks before hospital a...
Top 6 of 10 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Gilead Sciences, Inc. | GILD | 3 | PHASE3 | Viread, Tenofovir alafenamide |
| Vir Biotechnology, Inc. | VIR | 6 | PHASE3 | Tobevibart, Elebsiran |
| Bausch Health Companies Inc. | BHC | 1 | PHASE3 | Larsucosterol |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Daplusiran/Tomligisiran, Bepirovirsen |
| Aligos Therapeutics, Inc. | ALGS | 1 | PHASE2 | ALG-000184 |
| Precision BioSciences, Inc. | DTIL | 2 | PHASE1 | PBGENE-HBV |
Larsucosterol is an investigational small molecule being developed for the treatment of hepatitis, specifically alcohol-associated hepatitis. It is currently in Phase 3 clinical development and has not been approved by regulatory authorities.
Larsucosterol targets DNA methyltransferases (DNMTs), which are enzymes involved in epigenetic regulation. By modulating these enzymes, the drug aims to address the underlying mechanisms of alcohol-associated hepatitis.
Larsucosterol is being developed by Bausch Health Companies Inc., a company listed on the stock exchange under the ticker symbol BHC.
Larsucosterol is currently in Phase 3 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and efficacy.
Larsucosterol is being evaluated in a Phase 3 clinical trial with the identifier NCT07428538. This study is recruiting participants to assess the safety and efficacy of the drug in individuals with alcohol-associated hepatitis. The trial is randomized, double-blind, and placebo-controlled, with an estimated enrollment of 350 participants in the United States.